These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. Gracia M; Betriu À; Martínez-Alonso M; Arroyo D; Abajo M; Fernández E; Valdivielso JM; Clin J Am Soc Nephrol; 2016 Feb; 11(2):287-96. PubMed ID: 26668022 [TBL] [Abstract][Full Text] [Related]
4. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. Anguiano L; Riera M; Pascual J; Valdivielso JM; Barrios C; Betriu A; Clotet S; Mojal S; Fernández E; Soler MJ; Atherosclerosis; 2016 Oct; 253():135-143. PubMed ID: 27615597 [TBL] [Abstract][Full Text] [Related]
5. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. Valdivielso JM; Betriu A; Martinez-Alonso M; Arroyo D; Bermudez-Lopez M; Fernandez E; PLoS One; 2017; 12(10):e0186665. PubMed ID: 29045466 [TBL] [Abstract][Full Text] [Related]
6. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587 [TBL] [Abstract][Full Text] [Related]
7. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. Martín M; Valls J; Betriu A; Fernández E; Valdivielso JM Atherosclerosis; 2015 Jul; 241(1):264-70. PubMed ID: 25748053 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Betriu A; Martinez-Alonso M; Arcidiacono MV; Cannata-Andia J; Pascual J; Valdivielso JM; Fernández E; Nephrol Dial Transplant; 2014 Jul; 29(7):1415-22. PubMed ID: 24586070 [TBL] [Abstract][Full Text] [Related]
9. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. Arroyo D; Betriu A; Martinez-Alonso M; Vidal T; Valdivielso JM; Fernández E; BMC Nephrol; 2014 Oct; 15():168. PubMed ID: 25326683 [TBL] [Abstract][Full Text] [Related]
10. Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease. Valdivielso JM; Bozic M; Galimudi RK; Bermudez-López M; Navarro-González JF; Fernández E; Betriu À Nephrol Dial Transplant; 2019 Dec; 34(12):2079-2088. PubMed ID: 30010839 [TBL] [Abstract][Full Text] [Related]
11. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. Bozic M; Betriu A; Bermudez-Lopez M; Ortiz A; Fernandez E; Valdivielso JM; Clin J Am Soc Nephrol; 2018 Apr; 13(4):577-584. PubMed ID: 29519952 [TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817 [TBL] [Abstract][Full Text] [Related]
13. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Kawano N; Mori K; Emoto M; Lee E; Kobayashi I; Yamazaki Y; Urata H; Morioka T; Koyama H; Shoji T; Nishizawa Y; Inaba M Diabetes Res Clin Pract; 2011 Mar; 91(3):316-20. PubMed ID: 21227528 [TBL] [Abstract][Full Text] [Related]